Lynn M. Schuchter, MD, from the University of Pennsylvania, describes two trials presented at the 2013 ASCO Meeting looking at nivolumab in patients with melanoma.
Lynn M. Schuchter, MD
Advertisement
Articles by Lynn M. Schuchter, MD
Lynn M. Schuchter, MD, Chief, Hematology Oncology, Department of Medicine, University of Pennsylvania, discusses the treatment of advanced melanoma.
Dr. Lynn M. Schuchter from Penn Medicine on the Progression of Melanoma Care over the past 25 years
Dr. Lynn Schuchter from Penn Medicine Discusses Managing Ipilimumab's (Yervoy) Side Effects with the REMS program
Dr. Lynn M. Schuchter from Penn Med on the Next Steps in Melanoma Research
Dr. Lynn Schuchter chief of Hematology Oncology at Penn Medicine Reserves BRAF Testing for Advanced Melanoma
Dr. Schuchter chief of Hematology Oncology at Penn Medicine on Testing for a BRAF Mutation in Melanoma
Advertisement
Latest Updated Articles
Dr. Schuchter Discusses the Treatment of MelanomaPublished: July 3rd 2013 | Updated:
Dr. Schuchter Discusses Nivolumab in MelanomaPublished: August 21st 2013 | Updated:
Dr. Schuchter on Testing for a BRAF Mutation in MelanomaPublished: June 27th 2011 | Updated:
Dr. Schuchter Limits BRAF Testing to Advanced MelanomaPublished: June 30th 2011 | Updated:
Dr. Schuchter on the Next Steps in Melanoma ResearchPublished: July 7th 2011 | Updated:
Dr. Schuchter on Managing Ipilimumab's Side EffectsPublished: July 13th 2011 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5